Holen Sie sich die Stockscreener-App
143.53
1.52%
2.15
Handel nachbörslich:
142.61
-0.92
-0.64%
Schlusskurs vom Vortag:
$141.38
Offen:
$141.37
24-Stunden-Volumen:
956.39K
Relative Volume:
0.56
Marktkapitalisierung:
$7.05B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
17.92
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
-0.34%
1M Leistung:
+35.34%
6M Leistung:
-23.61%
1J Leistung:
-35.65%
1-Tages-Spanne:
$140.34
$143.82
1-Wochen-Bereich:
$135.11
$146.43
52-Wochen-Spanne:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
143.53 | 7.05B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
413.75 | 161.93B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.77 | 140.71B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
517.16 | 40.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.48 | 30.49B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
144.95 | 26.07B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Should You Continue to Hold Charles River Stock in Your Portfolio? - TradingView
Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of “Hold” by Brokerages - Defense World
Insider Sell: George Massaro Sells Shares of Charles River Labor - GuruFocus
Charles River Laboratories International (NYSE:CRL) Upgraded at TD Cowen - Defense World
Insider Sell: George Massaro Sells Shares of Charles River Laboratories International Inc (CRL) - GuruFocus
RNA Therapy Clinical Trials Market Top Companies StudyCharles - openPR.com
Charles River (CRL) Receives Upgrade and $179 Price Target | CRL Stock News - GuruFocus
We Think Charles River Laboratories International, Inc.'s (NYSE:CRL) CEO Compensation Package Needs To Be Put Under A Microscope - simplywall.st
Charles River (CRL) Upgraded to Buy Amid Potential Value Unlocki - GuruFocus
TD Cowen Upgrades Charles River Laboratories International to Buy From Hold, Adjusts PT to $179 From $105 - marketscreener.com
Unlocking Value: Strategic Divestitures and Market Leadership at Charles River Labs - TipRanks
Charles River Laboratories to Present at Bank of America Health Care Conference - BioSpace
Cell Banking Outsourcing Market: Executive Briefing & - openPR.com
Understanding Charles River (CRL) Reliance on International Revenue - Yahoo Finance
Human Microbiome Sequencing Market Top PlayersBaseclear - openPR.com
Charles river raises 2025 guidance with focus on NAMs and cost optimization - MSN
William Blair Has Bullish Forecast for CRL Q2 Earnings - Defense World
William Blair Analysts Raise Earnings Estimates for CRL - Defense World
Charles River extends gains as Evercore upgrades after Q1 beat - MSN
Barclays Increases Charles River Laboratories International (NYSE:CRL) Price Target to $155.00 - Defense World
Deutsche Bank lifts Charles River Labs target to $180 By Investing.com - Investing.com Nigeria
Morgan Stanley Cuts Price Target on Charles River Laboratories International to $168 From $184 - marketscreener.com
Barclays Keeps Their Hold Rating on Charles River Labs (CRL) - The Globe and Mail
Charles River surges after Q1 beat, guidance raise - MSN
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up - MSN
Evercore ISI lifts Charles River Labs stock rating to Outperform By Investing.com - Investing.com Canada
Charles River Labs Stock Soars On Strategic Review Plan With Elliott: Retail Investors Optimistic - MSN
What 10 Analyst Ratings Have To Say About Charles River - Benzinga
Charles River stock upgraded at Evercore ISI (CRL:NYSE) - Seeking Alpha
Charles River (CRL) Stock Target Price Raised by Barclays Analyst | CRL Stock News - GuruFocus
Charles River (CRL) Target Price Raised by Baird Analyst | CRL S - GuruFocus
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Earnings Call Transcript - Insider Monkey
Jefferies Adjusts Price Target on Charles River Laboratories International to $142 From $100, Maintains Hold Rating - marketscreener.com
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing? - Yahoo Finance
Charles River (CRL) Sees Price Target Boost After Positive Q1 Insights | CRL Stock News - GuruFocus
Charles River (CRL) Receives Boost After Q1 Success | CRL Stock News - GuruFocus
Charles River: Q1 Earnings Snapshot - Norwalk Hour
Charles River Laboratories International Inc (CRL) Q1 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance
Evercore ISI lifts Charles River Labs stock rating to Outperform - Investing.com
Charles River Laboratories International (NYSE:CRL) Shares Gap Up on Strong Earnings - Defense World
Deutsche Bank lifts Charles River Labs target to $180 - Investing.com
Charles River Laboratories Reports Q1 2025 Results - TipRanks
Decoding Charles River Laboratories International Inc (CRL): A S - GuruFocus
Health Care Stocks Climb As Companies Show Strong Gains - Finimize
Charles River Labs Stock Soars On Strategic Review Plan With Elliott: Retail Investors Optimistic By Stocktwits - Investing.com India
Charles River announces strategic review including 'examination of various alternatives' - MSN
Charles River Labs reshapes board, plans strategic review By Investing.com - Investing.com Canada
Charles River Labs Q1 2025 slides: Beats expectations, raises guidance amid NAMs transition - Investing.com Canada
Charles River (CRL) Stock Upgraded Following Strong Q1 Results | - GuruFocus
Charles River (CRL) Stock Upgraded Following Strong Q1 Results | CRL Stock News - GuruFocus
Charles River Laboratories International Q1 2025 Earnings Call Transcript - MarketBeat
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):